380 related articles for article (PubMed ID: 25990388)
1. Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.
Jiang W; Li X
Mol Diagn Ther; 2015 Jun; 19(3):141-58. PubMed ID: 25990388
[TBL] [Abstract][Full Text] [Related]
2. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy.
Olbjørn C; Cvancarova Småstuen M; Thiis-Evensen E; Nakstad B; Vatn MH; Perminow G
Scand J Gastroenterol; 2017 Apr; 52(4):414-419. PubMed ID: 27887202
[TBL] [Abstract][Full Text] [Related]
3. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes.
Bonneau J; Dumestre-Perard C; Rinaudo-Gaujous M; Genin C; Sparrow M; Roblin X; Paul S
Autoimmun Rev; 2015 Mar; 14(3):231-45. PubMed ID: 25462578
[TBL] [Abstract][Full Text] [Related]
4. New serological biomarkers of inflammatory bowel disease.
Li X; Conklin L; Alex P
World J Gastroenterol; 2008 Sep; 14(33):5115-24. PubMed ID: 18777587
[TBL] [Abstract][Full Text] [Related]
5. Serological antibodies in inflammatory bowel disease: a systematic review.
Prideaux L; De Cruz P; Ng SC; Kamm MA
Inflamm Bowel Dis; 2012 Jul; 18(7):1340-55. PubMed ID: 22069240
[TBL] [Abstract][Full Text] [Related]
6. Biological markers in inflammatory bowel disease: practical consideration for clinicians.
Mendoza JL; Abreu MT
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S158-73. PubMed ID: 20117339
[TBL] [Abstract][Full Text] [Related]
7. Role of MiRNAs in Inflammatory Bowel Disease.
Cao B; Zhou X; Ma J; Zhou W; Yang W; Fan D; Hong L
Dig Dis Sci; 2017 Jun; 62(6):1426-1438. PubMed ID: 28391412
[TBL] [Abstract][Full Text] [Related]
8. [Biomarkers in inflammatory bowel diseases].
Roblin X; Cavaille A; Clavel L; Paul S
Presse Med; 2014 Jan; 43(1):66-73. PubMed ID: 24373717
[TBL] [Abstract][Full Text] [Related]
9. Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.
Quetglas EG; Mujagic Z; Wigge S; Keszthelyi D; Wachten S; Masclee A; Reinisch W
World J Gastroenterol; 2015 Nov; 21(44):12519-43. PubMed ID: 26640330
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P
Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542
[TBL] [Abstract][Full Text] [Related]
11. The Role of Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Alpha Agents in Children and Adolescents with Inflammatory Bowel Disease.
Joosse ME; Samsom JN; van der Woude CJ; Escher JC; van Gelder T
Inflamm Bowel Dis; 2015 Sep; 21(9):2214-21. PubMed ID: 26284297
[TBL] [Abstract][Full Text] [Related]
12. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease.
Jaskowski TD; Litwin CM; Hill HR
Clin Vaccine Immunol; 2006 Jun; 13(6):655-60. PubMed ID: 16760323
[TBL] [Abstract][Full Text] [Related]
13. Emerging Biomarkers for the Diagnosis and Monitoring of Inflammatory Bowel Diseases.
Soubières AA; Poullis A
Inflamm Bowel Dis; 2016 Aug; 22(8):2016-22. PubMed ID: 27416044
[TBL] [Abstract][Full Text] [Related]
14. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
[TBL] [Abstract][Full Text] [Related]
15. The use of fecal calprotectin and lactoferrin in patients with IBD. Review.
Stragier E; Van Assche G
Acta Gastroenterol Belg; 2013 Sep; 76(3):322-8. PubMed ID: 24261027
[TBL] [Abstract][Full Text] [Related]
16. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin.
Sipponen T
Dig Dis; 2013; 31(3-4):336-44. PubMed ID: 24246984
[TBL] [Abstract][Full Text] [Related]
17. Serological markers in inflammatory bowel disease: a review of their clinical utility.
Barahona-Garrido J; Sarti HM; Barahona-Garrido MK; Hernández-Calleros J; Coss-Adame E; Garcia-Saenz SM; Yamamoto-Furusho JK
Rev Gastroenterol Mex; 2009; 74(3):230-7. PubMed ID: 19858012
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of inflammatory bowel disease.
Fengming Y; Jianbing W
Dis Markers; 2014; 2014():710915. PubMed ID: 24963213
[TBL] [Abstract][Full Text] [Related]
19. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers.
Schoepfer AM; Vavricka S; Zahnd-Straumann N; Straumann A; Beglinger C
J Crohns Colitis; 2012 May; 6(4):412-8. PubMed ID: 22398068
[TBL] [Abstract][Full Text] [Related]
20. Update of fecal markers of inflammation in inflammatory bowel disease.
Judd TA; Day AS; Lemberg DA; Turner D; Leach ST
J Gastroenterol Hepatol; 2011 Oct; 26(10):1493-9. PubMed ID: 21777275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
